Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces that Dr. J. Donald (Don) deBethizy has been appointed as Chairman of the Board of Directors. He replaces outgoing Chairman Prof. Dr. Gunther Hartmann who co-founded Rigontec and led the Board since 2014. Prof. Hartmann will remain on the Board of Directors.